Quince Therapeutics, Inc. Comprehensive Income
Quince Therapeutics, Inc. (QNCX) reported Comprehensive Income of -$75.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-14
- Quince Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$75.84M.
- Quince Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was $34.77M.
- Quince Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$40.00M.
- Quince Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$13.30M.
- Quince Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$78.19M.
- Quince Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$59.91M.
- Quince Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$28.05M.
- Quince Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$51.87M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$75.84M 10-Q · filed 2026-08-14 | -$41.07M 10-Q · filed 2026-08-14 | -$81.07M derived: sum of 3 quarters · filed 2026-08-14 | -$94.38M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $34.77M 10-Q · filed 2026-05-11 | -$5.23M derived: sum of 2 quarters · filed 2026-05-11 | -$18.53M derived: sum of 3 quarters · filed 2026-05-11 | -$30.38M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$40.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | -$53.31M derived: sum of 2 quarters · filed 2026-04-10 | -$65.16M derived: sum of 3 quarters · filed 2026-08-14 | -$78.19M 10-K · filed 2026-04-10 |
| 2025-09-30 | -$13.30M 10-Q · filed 2025-11-12 | -$25.16M derived: sum of 2 quarters · filed 2026-08-14 | -$38.19M 10-Q · filed 2025-11-12 | -$54.10M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$11.85M 10-Q · filed 2026-08-14 | -$24.89M 10-Q · filed 2026-08-14 | -$40.80M derived: sum of 3 quarters · filed 2026-08-14 | -$43.96M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$13.04M 10-Q · filed 2026-05-11 | -$28.95M derived: sum of 2 quarters · filed 2026-05-11 | -$32.11M derived: sum of 3 quarters · filed 2026-05-11 | -$60.58M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$15.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | -$19.07M derived: sum of 2 quarters · filed 2026-04-10 | -$47.54M derived: sum of 3 quarters · filed 2026-04-10 | -$59.91M 10-K · filed 2026-04-10 |
| 2024-09-30 | -$3.16M 10-Q · filed 2025-11-12 | -$31.63M derived: sum of 2 quarters · filed 2025-11-12 | -$44.00M 10-Q · filed 2025-11-12 | -$50.36M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$28.47M 10-Q · filed 2025-08-11 | -$40.84M 10-Q · filed 2025-08-11 | -$47.20M derived: sum of 3 quarters · filed 2025-08-11 | -$52.29M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$12.37M 10-Q · filed 2025-05-13 | -$18.73M derived: sum of 2 quarters · filed 2025-05-13 | -$23.83M derived: sum of 3 quarters · filed 2025-05-13 | -$28.49M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$6.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$11.46M derived: sum of 2 quarters · filed 2025-03-24 | -$16.12M derived: sum of 3 quarters · filed 2025-03-24 | -$28.05M 10-K · filed 2025-03-24 |
| 2023-09-30 | -$5.09M 10-Q · filed 2024-11-13 | -$9.76M derived: sum of 2 quarters · filed 2024-11-13 | -$21.69M 10-Q · filed 2024-11-13 | -$27.26M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$4.67M 10-Q · filed 2024-08-13 | -$16.59M 10-Q · filed 2024-08-13 | -$22.16M derived: sum of 3 quarters · filed 2024-08-13 | -$29.87M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$11.93M 10-Q · filed 2024-05-13 | -$17.50M derived: sum of 2 quarters · filed 2024-05-13 | -$25.20M derived: sum of 3 quarters · filed 2024-05-13 | -$41.73M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$5.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$13.28M derived: sum of 2 quarters · filed 2024-04-01 | -$29.80M derived: sum of 3 quarters · filed 2024-04-01 | -$51.87M 10-K · filed 2024-04-01 |
| 2022-09-30 | -$7.71M 10-Q · filed 2023-11-14 | -$24.23M derived: sum of 2 quarters · filed 2023-11-14 | -$46.30M 10-Q · filed 2023-11-14 | -$69.85M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$16.52M 10-Q · filed 2023-08-03 | -$38.59M 10-Q · filed 2023-08-03 | -$62.14M derived: sum of 3 quarters · filed 2023-08-03 | -$83.89M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$22.07M 10-Q · filed 2023-05-15 | -$45.62M derived: sum of 2 quarters · filed 2023-05-15 | -$67.37M derived: sum of 3 quarters · filed 2023-05-15 | -$89.19M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$23.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$45.30M derived: sum of 2 quarters · filed 2023-03-15 | -$67.13M derived: sum of 3 quarters · filed 2023-03-15 | -$90.34M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$21.75M 10-Q · filed 2022-11-09 | -$43.58M derived: sum of 2 quarters · filed 2022-11-09 | -$66.79M 10-Q · filed 2022-11-09 | -$87.54M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$21.83M 10-Q · filed 2022-08-09 | -$45.04M 10-Q · filed 2022-08-09 | -$65.79M derived: sum of 3 quarters · filed 2022-08-09 | -$87.50M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$23.21M 10-Q · filed 2022-05-10 | -$43.97M derived: sum of 2 quarters · filed 2022-05-10 | -$65.67M derived: sum of 3 quarters · filed 2022-05-10 | -$82.53M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$20.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$42.46M derived: sum of 2 quarters · filed 2022-03-01 | -$59.32M derived: sum of 3 quarters · filed 2022-03-01 | -$76.60M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$21.70M 10-Q · filed 2021-10-29 | -$38.57M derived: sum of 2 quarters · filed 2021-10-29 | -$55.84M 10-Q · filed 2021-10-29 | -$68.26M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$16.86M 10-Q · filed 2021-08-06 | -$34.14M 10-Q · filed 2021-08-06 | -$46.55M derived: sum of 3 quarters · filed 2022-03-01 | -$56.39M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$17.27M 10-Q · filed 2021-05-06 | -$29.69M derived: sum of 2 quarters · filed 2022-03-01 | -$39.53M derived: sum of 3 quarters · filed 2022-03-01 | -$48.49M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$12.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$22.26M derived: sum of 2 quarters · filed 2022-03-01 | -$31.22M derived: sum of 3 quarters · filed 2022-03-01 | -$36.87M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$9.84M 10-Q · filed 2020-11-12 | -$18.80M derived: sum of 2 quarters · filed 2020-11-12 | -$24.46M 10-Q · filed 2020-11-12 | -$27.96M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$8.96M 10-Q · filed 2020-08-14 | -$14.61M 10-Q · filed 2020-08-14 | -$18.12M derived: sum of 3 quarters · filed 2021-03-01 | -$20.65M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$5.66M 10-Q · filed 2020-05-12 | -$9.16M derived: sum of 2 quarters · filed 2021-03-01 | -$11.70M derived: sum of 3 quarters · filed 2021-03-01 | -$14.80M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$6.04M derived: sum of 2 quarters · filed 2021-03-01 | -$9.15M derived: sum of 3 quarters · filed 2021-03-01 | -$12.53M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$2.54M 10-Q · filed 2019-11-12 | -$5.64M derived: sum of 2 quarters · filed 2019-11-12 | -$9.02M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$3.11M 10-Q · filed 2019-08-09 | -$6.49M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | -$3.38M 10-Q · filed 2019-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |